2017
DOI: 10.1016/j.biochi.2017.04.012
|View full text |Cite
|
Sign up to set email alerts
|

Effects of phenothiazine-structured compounds on APP processing in Alzheimer's disease cellular model

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
17
1

Year Published

2018
2018
2022
2022

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 17 publications
(18 citation statements)
references
References 53 publications
0
17
1
Order By: Relevance
“…It is completely different from the amyloidogenic pathway, and the production of non-amyloidogenic pathway, sAPPα, has neurotropic and neuroprotective properties ( Meineck et al, 2016 ). There is wide consensus that activation of α-secretase could increase production of neuroprotective sAPPα ( Zhang et al, 2012 ; Corrigan et al, 2012a , b ; Jeong, 2017 ; Yuksel et al, 2017 ). In productive process of Aβ, BACE1 is responsible for the chief function of β-secretase ( Maloney and Lahiri, 2011 ).…”
Section: Discussionmentioning
confidence: 99%
“…It is completely different from the amyloidogenic pathway, and the production of non-amyloidogenic pathway, sAPPα, has neurotropic and neuroprotective properties ( Meineck et al, 2016 ). There is wide consensus that activation of α-secretase could increase production of neuroprotective sAPPα ( Zhang et al, 2012 ; Corrigan et al, 2012a , b ; Jeong, 2017 ; Yuksel et al, 2017 ). In productive process of Aβ, BACE1 is responsible for the chief function of β-secretase ( Maloney and Lahiri, 2011 ).…”
Section: Discussionmentioning
confidence: 99%
“…The drug therapies for AD are based on the cholinergic hypothesis that AD begins as a deficiency in the production of the neurotransmitter acetylcholine. Cholinesterase inhibition might impact the processing of amyloid in AD [ 51 ] and cholinesterase inhibitors have been suggested as the standard drugs for the treatment of AD. The inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) show potential in the treatment process of AD.…”
Section: Anti-aβ Effects Of Teamentioning
confidence: 99%
“…Due to the reciprocal connections between amyloid pathology and cholinergic function, the development of new ChEIs which reduce the hallmarks of AD has attracted great attention (13). Nowadays, cationic phenothiazine-derived compounds have shown to be prominent drug candidates for the treatment of AD due to their inhibitory effects on cholinesterase activity (14,15), Aβ pathology, and tau aggregation (16)(17)(18). Phenothiazines which are six-membered heterocyclic compounds containing nitrogen and sulfur were discovered during second half of the 19th century.…”
Section: Introductionmentioning
confidence: 99%
“…The findings showed that toluidine blue O (TBO) and thionine (TH) are highly potent inhibitors of both human BChE and human erythrocyte AChE with Ki in the nM-μM range (15). In addition, TBO was also found to affect amyloid precursor protein processing in-vitro and invivo models of AD (16,17). These results encouraged us to test whether a structurally closely related cationic phenothiazine compound, 1,9dimethyl-methylene blue (DMMB) (Figure 1) shows an inhibitory effect on human plasma BChE.…”
Section: Introductionmentioning
confidence: 99%